Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials

Ramez N. Eskander, Matthew A. Powell

Research output: Contribution to journalReview articlepeer-review

1 Scopus citations

Abstract

The treatment of advanced stage, metastatic or recurrent endometrial cancer remains a clinically difficult scenario. Although combination carboplatin and paclitaxel is an effective standard-of-care regimen, alternate strategies have shown promise, particularly in biomarker select populations. In an effort to improve oncologic outcomes, investigators are exploring novel immunotherapy combinations. In this review, we discuss the clinical rationale and design of current phase III immuno-oncology clinical trials in patients with advanced stage or recurrent endometrial cancer.

Original languageEnglish
JournalTherapeutic Advances in Medical Oncology
Volume13
DOIs
StatePublished - 2021

Keywords

  • antiangiogenic therapy
  • chemotherapy
  • combination therapy
  • endometrial cancer
  • immune checkpoint inhibition
  • immunotherapy
  • tumor mutational burden

Fingerprint

Dive into the research topics of 'Immunotherapy as a treatment strategy in advanced stage and recurrent endometrial cancer: review of current phase III immunotherapy clinical trials'. Together they form a unique fingerprint.

Cite this